StockData

IRulya Therapeutics Inc. (IRLA) stock

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$39.94−0.65 (-1.60%)

Close on Nov 19, 2026Market cap $40.62MP/E –Yield –

IRulya Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

IRulya Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$47.00M. For fiscal 2025 it was -$41.78M. The highest annual figure on record is -$11.91M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$41.78M–
FY2024Dec 31, 2024-$32.16M–
FY2023Dec 31, 2023-$18.45M–
FY2022Dec 31, 2022-$44.17M–
FY2021Dec 31, 2021-$63.11M–
FY2020Dec 31, 2020-$50.87M–
FY2019Dec 31, 2019-$33.33M–
FY2018Dec 31, 2018-$11.91M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.89M–
Q1 FY2026Mar 31, 2026-$7.63M–
Q4 FY2025Dec 31, 2025-$10.49M–
Q3 FY2025Sep 30, 2025-$10.00M–
Q2 FY2025Jun 30, 2025-$11.54M–
Q1 FY2025Mar 31, 2025-$9.75M–
Q4 FY2024Dec 31, 2024-$7.69M–
Q3 FY2024Sep 30, 2024-$7.31M–
Q2 FY2024Jun 30, 2024-$8.78M–
Q1 FY2024Mar 31, 2024-$8.39M–
Q4 FY2023Dec 31, 2023-$6.10M–
Q3 FY2023Sep 30, 2023-$4.82M–
Q2 FY2023Jun 30, 2023-$3.83M–
Q1 FY2023Mar 31, 2023-$3.71M–
Q4 FY2022Dec 31, 2022-$5.91M–
Q3 FY2022Sep 30, 2022-$6.75M–
Q2 FY2022Jun 30, 2022-$15.42M–
Q1 FY2022Mar 31, 2022-$16.10M–
Q4 FY2021Dec 31, 2021-$14.46M–
Q3 FY2021Sep 30, 2021-$17.34M–
Q2 FY2021Jun 30, 2021-$17.66M–
Q1 FY2021Mar 31, 2021-$13.65M–
Q4 FY2020Dec 31, 2020-$13.29M–
Q3 FY2020Sep 30, 2020-$12.39M–
Q2 FY2020Jun 30, 2020-$14.41M–
Q1 FY2020Mar 31, 2020-$10.78M–
Q4 FY2019Dec 31, 2019-$10.96M–
Q3 FY2019Sep 30, 2019-$8.82M–
Q2 FY2019Jun 30, 2019-$6.28M–
Q1 FY2019Mar 31, 2019-$7.27M–
Q4 FY2018Dec 31, 2018-$3.97M–
Q3 FY2018Sep 30, 2018-$2.12M–

More IRulya Therapeutics figures

See a number that looks wrong?